Paul Hastings (Europe) LLP has advised EQT in connection with its investment in Cerba HealthCare

Paris – Paul Hastings (Europe) LLP has advised EQT Private Equity, a purpose-driven global investment organization with over EUR 52 billion in assets under management, in connection with its investment in Cerba HealthCare, a leading player in medical diagnosis.

Cerba HealthCare, headquartered in France and firmly established in Europe and Africa through its historical routine and specialty biology expertise, also operates globally through its clinical trials business unit for the validation of new compounds and vaccines. It stands as a unique group in the diagnosis market, covering the needs for diagnostic tools and expertise for patients, physicians, hospitals and the pharmaceutical industry.

Paul Hastings’ team, for this transaction, was composed of Arthur de Baudry d'Asson and Alexis Terray (partners), Nicolas Lovas and Mathilde Carré for corporate matters, Olivier Vermeulen (partner) for finance matters, Allard de Waal (partner) for tax matters and Camille Paulhac (partner) for regulatory and anti-trust matters.

EQT Private Equity was also advised by Freshfields Bruckhaus Deringer.

The management team of Cerba HealthCare has been advised by Weil, Gotshal & Manges LLP and PSP Investments has been advised by Latham & Watkins LLP.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.